PIK3CA and Hodgkins lymphoma: Clinical trials with CAL-101 and other PI3K inhibitors are on-going and have expanded to other B cell malignancies including MM, NHL, FL, HL, small lymphocytic lymphoma, and acute myeloid lymphoma.